| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a cancer therapeutic drug without containing an anthracycline derivative being a chemotherapeutic agent which easily causes side effects in cancer therapies. <P>SOLUTION: There is provided a cancer therapeutic drug for human patients susceptible to or diagnosed as a disorder by overexpression of ErbB2, which includes a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than anthracycline derivatives. As the chemotherapeutic agent, a taxoid, particularly paclitaxel or docetaxel is preferable. The treatment drug is effective particularly to breast cancer. <P>COPYRIGHT: (C)2013,JPO&INPIT |
